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BACKGROUND
The effectiveness of surgery versus observation for men with localized prostate 
cancer detected by means of prostate-specific antigen (PSA) testing is not known.
METHODS
From November 1994 through January 2002, we randomly assigned 731 men with 
localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter) 
to radical prostatectomy or observation and followed them through January 2010. 
The primary outcome was all-cause mortality; the secondary outcome was prostate-
cancer mortality.
RESULTS
During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radi-
cal prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation 
(hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P = 0.22; absolute risk 
reduction, 2.9 percentage points). Among men assigned to radical prostatectomy, 
21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%) 
assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P = 0.09; absolute 
risk reduction, 2.6 percentage points). The effect of treatment on all-cause and 
prostate-cancer mortality did not differ according to age, race, coexisting conditions, 
self-reported performance status, or histologic features of the tumor. Radical pros-
tatectomy was associated with reduced all-cause mortality among men with a PSA 
value greater than 10 ng per milliliter (P = 0.04 for interaction) and possibly among 
those with intermediate-risk or high-risk tumors (P = 0.07 for interaction). Adverse 
events within 30 days after surgery occurred in 21.4% of men, including one death.
CONCLUSIONS
Among men with localized prostate cancer detected during the early era of PSA test-
ing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer 
mortality, as compared with observation, through at least 12 years of follow-up. 
Absolute differences were less than 3 percentage points. (Funded by the Department 
of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials 
.gov number, NCT00007644.)
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The treatment of early-stage pros-tate cancer remains controversial, especially for tumors detected by means of prostate-
specific antigen (PSA) testing.1 Systematic reviews 
have provided inadequate information for assess-
ing the comparative effectiveness of treatments 
and any associated harms.2 Although the lifetime 
risk of receiving a diagnosis of prostate cancer is 
about 17%, the risk of dying from the disease is 
approximately 3%, suggesting that conservative 
management may be appropriate for many men.3,4
Two randomized trials compared radical pros-
tatectomy with observation but were conducted 
before PSA testing became widespread.5,6 One 
study failed to show a significant difference in 
overall mortality after more than 20 years.5 An-
other showed absolute differences in all-cause and 
prostate-cancer mortality at 15 years of 6.6 per-
centage points and 6.1 percentage points, respec-
tively, in favor of surgery.6 Benefits were confined 
to men younger than 65 years of age. A random-
ized trial comparing external-beam radiotherapy 
with observation, also among men who received 
the diagnosis before PSA testing became wide-
spread, showed no significant differences in mor-
tality through at least 16 years.7 During the era of 
PSA testing, an observational study showed high 
10-year survival rates among men treated conser-
vatively.8 Despite excellent long-term, disease-spe-
cific survival with observation, this option is rarely 
used, in part because of a lack of evidence from 
randomized trials comparing observation with at-
tempted curative treatment for prostate cancer de-
tected since PSA testing became common prac-
tice. We conducted a randomized trial to compare 
radical prostatectomy with observation in 731 men 
who had received a diagnosis of clinically localized 
prostate cancer in the early era of PSA testing.
ME THODS
STUDY DESIGN
We previously reported the baseline characteris-
tics of the patients and the design of the Prostate 
Cancer Intervention versus Observation Trial 
(PIVOT).9 Enrollment began in November 1994 
and ended in January 2002, with follow-up 
through January 2010. We recruited men from 44 
Department of Veterans Affairs sites and 8 Na-
tional Cancer Institute sites.
The research protocol was approved by the in-
stitutional review board at each site. All patients 
provided written informed consent. Randomiza-
tion was stratified according to site and imple-
mented by means of a central interactive telephone 
system.
Patients had to be medically fit for radical 
prostatectomy and to have histologically con-
firmed, clinically localized prostate cancer (stage 
T1-T2NxM0 in the tumor–node–metastasis classi-
fication system according to the American Joint 
Committee on Cancer10) of any grade diagnosed 
within the previous 12 months. Patients also had 
to have a PSA value of less than 50 ng per milli-
liter, an age of 75 years or less, negative results 
on a bone scan for metastatic disease, and a life 
expectancy of at least 10 years from the time of 
randomization. The study sites assessed eligibil-
ity on the basis of locally obtained PSA values and 
biopsy readings. After randomization, a central 
pathologist reviewed the biopsy and radical-pros-
tatectomy specimens, and a central laboratory 
measured PSA.
TREATMENT PROTOCOL
The technique used for radical prostatectomy was 
at the surgeon’s discretion. Additional interven-
tions were determined by each participant and his 
physician. Men randomly assigned to the observa-
tion group were offered palliative therapy or che-
motherapy for symptomatic or metastatic pro-
gression.
FOLLOW-UP AND CLINICAL OUTCOMES
We scheduled study visits every 6 months for a 
minimum of 8 years and a maximum of 15 years 
or until the patient died. Bone scans were ob-
tained at 5, 10, and 15 years or at the last visit for 
persons with less than 15 years of follow-up, 
with additional scans obtained at the clinician’s 
discretion. The primary outcome was all-cause 
mortality. Our secondary outcome was prostate-
cancer mortality, which was defined as death that 
was definitely or probably due to prostate cancer 
or definitely or probably due to prostate-cancer 
treatment by a three-member end-points commit-
tee that was unaware of the study assignments. 
Bone metastases were documented on the basis of 
positive results of bone scanning or skeletal radi-
ography. We assessed 30-day perioperative harms 
and the prevalence of urinary incontinence and 
erectile and bowel dysfunction at 2 years, which 
was based on self-reported dysfunction that was 
at least moderate in severity.
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STUDY OVERSIGHT
The authors are responsible for the study design 
and oversight and the analysis and reporting of the 
data. All authors vouch for the accuracy of the data 
and the fidelity of the study to the protocol. The 
site investigators and assistants collected and trans-
mitted data to the coordinating center for analy-
sis. An independent data and safety monitoring 
board monitored the trial for safety and scientific 
integrity. Interim analyses were stipulated in the 
protocol.
STATISTICAL ANALYSIS
We carried out analyses according to the intention-
to-treat principle. Recruitment difficulties pre-
vented the attainment of our original goal of en-
rolling 2000 men. We revised our sample on the 
basis of estimates that 740 men enrolled over a 
period of 7 years, with an additional 8 years of 
follow-up, would provide 91% power to detect a 
25% relative reduction in all-cause mortality, as-
suming a median survival of 10 years. The data and 
safety monitoring board reviewed and approved 
this revision. For assessment of the secondary end 
point (death from prostate cancer or treatment), a 
survival analysis was performed in which the data 
from surviving patients were censored at the end 
of the study and the data from patients who died 
from causes other than prostate cancer were cen-
sored at the date of death from that other cause.11
We analyzed death from any cause, death from 
prostate cancer (with death from other causes 
treated as a competing risk), and bone metasta-
ses. Outcomes were analyzed with the use of a 
proportional-hazards model, which provided haz-
ard ratios and corresponding 95% confidence in-
tervals. Cumulative incidence and between-group 
differences were assessed at 4, 8, and 12 years 
and at the end of the study. P values of less than 
0.05 (two-sided) were considered to indicate sta-
tistical significance.
Mortality and bone metastases were estimated 
for each study group with the Kaplan–Meier 
method. Seven subgroups defined according to 
baseline characteristics were prespecified for as-
sessment of overall and prostate-cancer mortality 
and were specified post hoc for assessment of bone 
metastases: age (<65 years vs. ≥65 years), race 
(white, black, or other), coexisting conditions 
(Charlson comorbidity index score, 0 vs. ≥1),12 
self-reported performance status (0 [fully active] 
vs. 1 to 4, with higher scores indicating poorer 
functional status), PSA level (≤10 vs. >10 ng per 
milliliter), score on the Gleason histologic scale 
(<7 vs. ≥7 on a scale of 2 to 10, with 10 indicat-
ing the most poorly differentiated tumors),10,13 and 
D’Amico tumor risk score (low, intermediate, or 
high), which was based on tumor stage, the his-
tologic score assigned by the local study site, and 
the PSA level.14
To determine whether the treatment effect var-
ied according to subgroup, we performed tests of 
interaction between group assignment and risk-
factor category. Modification of the effect of radi-
cal prostatectomy according to subgroup was as-
sessed by means of a Cox proportional-hazards 
model that included an interaction term between 
subgroup category and study group. A P value of 
less than 0.05 was considered to indicate statisti-
cal significance, with no correction for multiple 
comparisons. We performed sensitivity analyses 
using centrally assessed histopathological findings 
and PSA values. We used SAS software, version 9.2 
(SAS Institute), for all analyses.11 The protocol, 
including the statistical analysis plan, is available 
with the full text of this article at NEJM.org.
R ESULT S
CHARACTERISTICS OF THE PARTICIPANTS
Among 13,022 men with prostate cancer (Fig. 1), 
5023 were eligible for enrollment. A total of 731 
men (14.6%) agreed to participate and underwent 
randomization to radical prostatectomy (364 men) 
or observation (367). The mean age was 67 years 
(see Table 1 in the Supplementary Appendix, avail-
able at NEJM.org). Nearly one third of the patients 
were black; 85% reported full independence in 
activities of daily living. The median PSA value was 
7.8 ng per milliliter (mean, 10.1). About 50% of 
the men had stage T1c disease (not palpable, de-
tected by means of PSA testing), and about 25% 
had histologic scores of 7 or higher on the Gleason 
scale; 40% of the men had low-risk, 34% inter-
mediate-risk, and 21% high-risk prostate cancer 
(about 5% had missing data). On the basis of 
central pathological review, 48% of the patients 
had histologic scores of 7 or higher on the Gleason 
scale, and 66% had tumors in the intermediate-
risk or high-risk categories.
TREATMENT ADHERENCE
During follow-up, 287 of the 364 men (78.8%) who 
were randomly assigned to radical prostatectomy 
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underwent an attempted radical prostatectomy 
(median time from randomization to surgery, 35 
days; interquartile range, 24 to 50), and 311 (85.4%) 
received definitive therapy (median time from ran-
domization to definitive therapy, 36 days; inter-
quartile range, 24 to 59). Among men assigned to 
the observation group, 37 (10.1%) underwent an at-
tempted radical prostatectomy (median time from 
randomization to surgery, 61 days; interquartile 
range, 30 to 624) (Fig. 1), and 75 (20.4%) received 
definitive therapy (median time from randomiza-
tion to initiation of treatment, 652 days; interquar-
tile range, 61 to 1502). Median follow-up from 
randomization until death or the end of the study 
was 10.0 years (interquartile range, 7.3 to 12.6).
SURGICAL TECHNIQUE AND PATHOLOGICAL 
FINDINGS
Of the 281 radical-prostatectomy procedures per-
formed in men in the radical-prostatectomy group 
(Fig. 1), nerve-sparing surgery was used in 108 
(38.4%) (Table 2 in the Supplementary Appendix). 
On the basis of local pathological findings, the 
tumor was confined to the prostate in 150 men 
(53.4%), including 65.8% of those with low-risk 
prostate cancer (75 of 114 men) and 35.6% of 
those with high-risk disease (21 of 59). Capsular 
invasion was noted in 28 men (10.0%) and capsu-
lar penetration in 16 (5.7%). Surgical margins were 
positive for tumor in 64 men (22.8%).
ALL-CAUSE MORTALITY
By the end of the study, 354 men (48.4%) had died 
(Table 3 in the Supplementary Appendix). Among 
men in the radical-prostatectomy group, 171 
(47.0%) died, as compared with 183 (49.9%) in the 
observation group (hazard ratio, 0.88; 95% confi-
dence interval [CI], 0.71 to 1.08; P = 0.22; absolute 
risk reduction, 2.9 percentage points; 95% CI, 
−4.1 to 10.3) (Fig. 2A, and Table 4 in the Supple-
mentary Appendix).
Median survival was 13.0 years (95% CI, 12.2 
to 13.7) in the radical-prostatectomy group and 
12.4 years (95% CI, 11.4 to 13.1) in the observa-
tion group. At 12 years, 40.9% of men assigned 
to radical prostatectomy and 43.9% of those as-
signed to observation had died. The absolute re-
duction in mortality with radical prostatectomy 
was not significant at any interval and declined 
over time, from 4.6 percentage points (95% CI, 
−0.2 to 9.3) at 4 years to 2.9 percentage points 
(95% CI, −4.2 to 10.0) at 12 years.
PROSTATE-CANCER MORTALITY
Death attributed to prostate cancer or treatment 
occurred in 52 men (7.1%) (Table 3 in the Supple-
mentary Appendix). In the radical-prostatectomy 
group, 21 of 364 men (5.8%) died from prostate 
cancer or treatment, as compared with 31 of 367 
(8.4%) in the observation group (hazard ratio, 0.63; 
95% CI, 0.36 to 1.09; P = 0.09; absolute risk reduc-
tion, 2.6 percentage points; 95% CI, −1.1 to 6.5) 
(Fig. 2B). Two thirds of the deaths due to prostate 
cancer (34 of 52 deaths, accounting for 4.7% of all 
patients) were considered to be definitely due to 
prostate cancer or treatment, with no significant 
difference between the groups: 16 men (4.4%) in 
the radical-prostatectomy group and 18 (4.9%) in 
the observation group. Prostate-cancer mortality 
was identical in the observation and radical-pros-
tatectomy groups at 4 years. At 12 years, radical 
prostatectomy was associated with a nonsignifi-
cant absolute reduction in mortality of 3.0 per-
731 Underwent randomization
13,022 Men with newly diagnosed prostate
cancer entered into screening registry
5023 Were eligible
4292 Declined to participate
364 Were assigned to radical-prostatec-
tomy group
281 Underwent radical prostatectomy
53 Underwent observation
6 Underwent attempted radical 
prostatectomy but incomplete
owing to positive lymph nodes
14 Underwent EBRT
9 Underwent brachytherapy
1 Underwent unspecified irradiation
367 Were assigned to observation group
292 Underwent observation
36 Underwent radical prostatectomy





Figure 1. Study Enrollment and Treatment.
Of a total of 13,022 men who were screened for participation, 5023 were  
eligible for enrollment; of these, 731 were randomly assigned to radical 
prostatectomy or observation. Of the 364 men in the radical-prostatectomy 
group, 287 underwent attempted surgery, as did 37 of the 367 men in the 
observation group. EBRT denotes external-beam radiotherapy.
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centage points, as compared with observation 
(4.4 vs. 7.4 percentage points; relative risk, 0.60; 
95% CI, 0.33 to 1.09), declining slightly at the 
end of the study (Fig. 2B, and Table 5 in the Sup-
plementary Appendix).
BONE METASTASES
Bone metastases occurred in 17 men assigned to 
radical prostatectomy (4.7%), as compared with 39 
(10.6%) assigned to observation (hazard ratio, 0.40; 
95% CI, 0.22 to 0.70; P<0.001) (Fig. 1 and Table 6 
in the Supplementary Appendix). Differences in the 
cumulative incidence between the radical-prosta-
tectomy and observation groups changed little af-
ter 8 years of follow-up.
SUBGROUP AND SENSITIVITY ANALYSES
All-Cause Mortality
The effect of radical prostatectomy, as compared 
with observation, on all-cause mortality did not 
differ significantly according to age, score on the 
Gleason histologic scale, race, self-reported perfor-
mance status, or score on the Charlson comorbid-
ity index. We identified a significant interaction 
between study group and baseline PSA value 
(P = 0.04 for interaction) and a borderline interac-
tion (P = 0.07) for tumor risk category (Fig. 3A, 
and Table 3 in the Supplementary Appendix). As 
compared with observation, surgery did not re-
duce all-cause mortality among men with a PSA 
value of 10 ng per milliliter or less (median, 6.0) 
(hazard ratio, 1.03; 95% CI, 0.79 to 1.35). Among 
men with a PSA value greater than 10 ng per mil-
liliter (median, 15.0), surgery reduced all-cause 
mortality by 13.2% (hazard ratio, 0.67; 95% CI, 
0.48 to 0.94) (Fig. 2A and 2B and Table 4 in the 
Supplementary Appendix).
Among men with intermediate-risk tumors (as 
determined by a PSA value of 10.1 to 20.0 ng per 
milliliter, a score of 7 on the Gleason scale, or a 
stage T2b tumor), those who were randomly as-
signed to surgery had a 31% relative reduction in 
all-cause mortality, as compared with those as-
signed to observation (hazard ratio, 0.69; 95% CI, 
0.49 to 0.98; absolute risk reduction, 12.6 percent-
age points). Among men with high-risk tumors, 
surgery resulted in a nonsignificant absolute 
reduction in mortality of 6.7 percentage points, 
as compared with observation (P = 0.16) (Fig. 2C, 
2D, and 2E in the Supplementary Appendix). In 
contrast, among men with low-risk cancers (as 
determined by a PSA value ≤10 ng per milliliter, 
a score of 6 or less on the Gleason scale, and a 
stage T1a–c or T2a tumor), there was a 15% non-
significant increase in mortality among men ran-
domly assigned to radical prostatectomy, as com-
pared with those assigned to observation (hazard 
ratio, 1.15; 95% CI, 0.80 to 1.66). The absolute 
difference at 12 years was 5.4 percentage points, 
in favor of observation over surgery (37.2% vs. 
31.8%). Sensitivity analyses performed with the 
use of central biopsy readings showed no signifi-
cant differences in all-cause mortality between 
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Figure 2. Kaplan–Meier Plots of Mortality.
By the end of the study, 354 men (48.4%) had died from any cause (Panel A). 
Death attributed to prostate cancer or treatment occurred in 52 men (7.1%) 
(Panel B). Data from the radical-prostatectomy group are shown in red, and 
data from the observation group in blue.
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to scores on the Gleason scale or tumor risk 
categories (P>0.13 for all categories). When local 
histologic findings for men with intermediate-
risk disease and those with high-risk disease were 
pooled, radical prostatectomy was associated with 
an absolute reduction in all-cause mortality of 
10.5 percentage points (hazard ratio, 0.71; 95% 
CI, 0.54 to 0.92; P = 0.01). The reduction in mor-
tality was smaller and was not significant when 
the pooled data were assessed on the basis of 
central pathological review (hazard ratio, 0.81; 
95% CI, 0.63 to 1.0; P = 0.10; absolute risk reduc-
tion, 4.7 percentage points).
Prostate-Cancer Mortality
As compared with observation, the effect of radi-
cal prostatectomy on prostate-cancer mortality did 
not differ significantly according to age, race, 
score on the Charlson comorbidity index, or self-
reported performance status (Fig. 3B). We found 
some evidence of treatment interaction for sub-
groups defined by PSA value and tumor risk cat-
egory (P = 0.11 for interaction for both compari-
sons). Prostate-cancer mortality was lower in the 
radical-prostatectomy group than in the observa-
tion group among men with a PSA value of more 
than 10 ng per milliliter (5.6% vs. 12.8%, P = 0.02) 
and among men with high-risk prostate cancer 
(9.1% vs. 17.5%, P = 0.04). However, prostate-can-
cer mortality was not significantly lower in the 
radical-prostatectomy group among men with a 
PSA level of 10 ng per milliliter or less (P = 0.82) or 
among those with low-risk tumors (P = 0.54) or in-
termediate-risk tumors (P = 0.12) (Fig. 3A through 
3E and Table 5 in the Supplementary Appendix).
The results for prostate-cancer mortality were 
generally consistent when we substituted central 
for local PSA measures and histopathological find-
ings. However, among men with intermediate-
risk prostate cancer, the absolute risk difference 
of 4.6 percentage points in favor of radical pros-
tatectomy on the basis of local histologic findings 
changed to 1.3 percentage points in favor of ob-
servation, on the basis of central histologic find-
ings. Bone metastases were not reduced among 
men with PSA values of 10 ng per milliliter or less 
or among those with low-risk disease. Among 
men with PSA levels that were greater than 10 ng 
per milliliter or with intermediate-risk or high-
risk disease, absolute reductions of approximately 
9.0 to 11.0 percentage points occurred. Subgroup 
differences in cumulative incidence remained sta-
ble after about 8 years (Table 6 in the Supplemen-
tary Appendix).
SURGICAL MORBIDITY
Perioperative complications during the first 30 days 
after surgery occurred in 21.4% of men in the 
radical-prostatectomy group who underwent rad-
ical prostatectomy and included one death. The 
most common complication was wound infec-
tion, in 4.3% of the men (Table 1). Complications 
occurring in more than 2% of the men included 
urinary tract infection, surgical repair, bleeding 
requiring transfusion, and urinary catheterization 
more than 30 days after surgery. At 2 years, pa-
tient-reported urinary incontinence and erectile 
dysfunction, but not bowel dysfunction, were sig-
nificantly more common among men who were 
randomly assigned to radical prostatectomy than 
among those randomly assigned to observation 
(Table 2).
Discussion
Among men with clinically localized prostate 
cancer that had been diagnosed after PSA testing 
came into practice, our study showed that radical 
prostatectomy did not reduce all-cause or prostate-
cancer mortality, as compared with observation, 
through at least 12 years of follow-up. Confidence 
intervals for the effect size indicated that surgery 
did not reduce all-cause mortality by more than 
Figure 3 (facing page). Forest Plots for Primary 
and Secondary Outcomes.
There were no significant between-group differences in 
all-cause mortality according to age, score on the Glea-
son histologic scale (<7 vs. ≥7 on a scale of 2 to 10, with 
10 indicating the most poorly differentiated tumors),13 
self-reported race, self-reported performance status  
(0 [fully active] vs. 1 to 4, with higher scores indicating 
poorer functional status), or score on the Charlson co-
morbidity index12 (Panel A), but there was a significant 
interaction between study group and baseline PSA value 
(P = 0.04 for interaction) and a borderline interaction 
(P = 0.07) for tumor risk (D’Amico tumor risk score 
[low, intermediate, or high], which was based on tumor 
stage, histologic score, and PSA level14). Prostate-cancer 
mortality did not differ significantly between the study 
groups according to age, race, score on the Charlson 
comorbidity index, or self-reported performance status 
(Panel B), although there was borderline evidence of 
an interaction for PSA value and tumor-risk category 
(P = 0.11 for interaction for both comparisons). The bars 
indicate 95% confidence intervals, and the size of the 
symbol indicates the weight of the estimate.
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10% and might have increased mortality by as 
much as 4%. Differences in all-cause mortality de-
creased over time, suggesting that longer follow-
up would not alter these findings. Only 10% of 
patients were younger than 60 years of age. Lon-
ger follow-up may be important for the minority 
of men with prostate cancer who were younger 
than 60 years of age. However, the nonsignificant 
between-group difference in prostate-cancer mor-
tality and the significant 6% reduction in bone 
metastases with radical prostatectomy remained 
fairly constant after 8 years. Our findings add to 
evidence supporting observation, and possibly ac-
tive surveillance, for most men who receive a diag-
nosis of localized prostate cancer, especially those 
with a low PSA value or low-risk disease.2,3,6,8,15-24
Death due to prostate cancer or treatment oc-
curred infrequently, in 7.1% of patients. Any dif-
ferences in prostate-cancer mortality between sur-
gery and observation occurred primarily among 
men whose death was judged as probably due to 
prostate cancer or treatment. Among men whose 
death was considered to be definitely due to pros-
tate cancer or treatment, we found almost no dif-
ference between surgery and observation. Be-
tween-group differences in the time of death due 
to prostate cancer or treatment did not explain 
the differences in all-cause mortality in the entire 
cohort or the subgroups. These findings high-
light the limitations of using prostate-cancer 
mortality as an outcome, even with the use of ad-
judication committees whose members are un-
aware of treatment assignments and who are fol-
lowing standardized protocols.25-27
The effect of radical prostatectomy on mortal-
ity did not vary according to age, race, self-report-
ed performance status, or coexisting conditions, 
but our findings suggest that it may vary accord-
ing to PSA value and possibly tumor risk. Positive 
results were from multiple subgroup compari-
sons; the tests of interaction typically approached 
but did not reach significance and may therefore 
be due to chance. Among men with PSA levels of 
10 ng per milliliter or less, all-cause mortality was 
slightly lower at 12 years in the observation group 
than in the radical-prostatectomy group; prostate-
cancer mortality in the observation group was 
6%, with a nonsignificant absolute reduction of 
less than 1.0 percentage point in the radical-
prostatectomy group. Among men with low-risk 
disease, observation was associated with a non-
significant reduction in all-cause and prostate 
cancer mortality, with no significant between-
group difference in bone metastases. Among men 
with a PSA value that was greater than 10 ng per 
milliliter and possibly among those with interme-
diate-risk or high-risk prostate cancer (as deter-
mined according to the PSA value, local histo-
logic findings, and stage), absolute reductions in 
all-cause mortality with radical prostatectomy 
ranged from 6.7 to 13.2 percentage points. Re-
ductions were smaller and not significant when 
central histopathological findings were used, and 
we found no significant reductions with radical 
prostatectomy in categories that were derived 
solely on the basis of higher scores on the Gleason 
histologic scale or tumor stage. Reductions in 
prostate-cancer mortality in the radical-prosta-
tectomy group were limited to men with a PSA 
value that was greater than 10 ng per milliliter and 
to those with high-risk disease, with absolute 
reductions of 7.2 to 8.4 percentage points. Abso-
lute reductions in bone metastases of 10.4 and 
8.6 percentage points occurred, respectively, in 








Wound infection 12 (4.3)
Urinary tract infection 7 (2.5)
Sepsis 3 (1.1)
Deep-vein thrombosis 2 (0.7)
Stroke 1 (0.4)
Pulmonary embolism 2 (0.7)
Myocardial infarction 3 (1.1)
Renal failure or dialysis 1 (0.4)
Bowel injury requiring surgical repair 3 (1.1)
Additional surgical repair 7 (2.5)
Bleeding requiring transfusion 6 (2.1)





* Of the 364 men randomly assigned to the radical-prosta-
tectomy group, radical prostatectomy was completed in 
280. Multiple events may have occurred in a single patient.
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 29, 2014. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Treatment or Observation for Localized Prostate Cancer
n engl j med 367;3 nejm.org july 19, 2012 211
men with a PSA value of 10 ng per milliliter or 
higher and in those with high-risk disease.
As compared with the Scandinavian Prostate 
Cancer Group 4 (SPCG-4) trial of radical prosta-
tectomy versus watchful waiting in men with pros-
tate cancer detected before widespread PSA test-
ing,6 PIVOT enrolled a higher percentage of men 
with nonpalpable tumors (stage T1c, 50% vs. 12%) 
and with PSA values of 10 ng per milliliter or 
lower. Treatment adherence was similar in the 
two trials.6,28 In contrast to the SPCG-4 trial, we 
did not find a significant reduction in all-cause 
or prostate-cancer mortality with radical prostatec-
tomy. Our findings are particularly robust among 
men with a PSA value of 10 ng per milliliter or 
less, including men with a score of 7 or higher on 
the Gleason histologic scale, and low-risk tumor 
— categories that were underrepresented in the 
SPCG-4 trial. Unlike the SPCG-4 trial, our study 
did not show that the effect of surgery, as com-
pared with observation, varied according to age. 
Although hazard ratios indicated that the relative 
effect of radical prostatectomy on prostate-cancer 
mortality was similar in PIVOT and the SPCG-4 
trial (37% and 38% reduction, respectively), the 
relative reduction in all-cause mortality in our 
study was less than half that in the SPCG-4 trial 
(12% vs. 25%), as were the absolute reductions 
in all-cause mortality (2.9 percentage points vs. 
6.6 percentage points) and prostate-cancer mor-
tality (2.6 percentage points vs. 6.1 percentage 
points); the overall percentage of men who died 
from prostate cancer was also lower in our study 
(7.1% vs. 19.6%). The mortality reductions in our 
study were not significant and probably reflect 
the more favorable prognosis for patients with 
tumors detected by means of PSA testing.
Our study has strengths that enhance the clini-
cal applicability of the findings. The age, health 
status, PSA value, and tumor-risk characteristics of 
the men enrolled in this study were similar to 
those of both men who were eligible but declined 
to undergo randomization9 and men in the gen-
eral population who have received a diagnosis of 
prostate cancer.1-3,8,29 Perioperative morbidity and 
mortality were similar to those previously report-
ed.28,30 The percentage of men with positive surgi-
cal margins was similar to that in earlier studies 
and lower than that in the SPCG-4 trial.27 The tu-
mor volumes and PSA values in our study popula-
tion, although higher than in some contemporary 
series,31-35 are probably representative of those in 
the general population of men who received a di-
agnosis of prostate cancer at the time the study 
was being conducted. Our choice of all-cause mor-
tality as the primary outcome underscores the 
importance of improving life expectancy with can-
cer treatment and eliminates the possibility of bi-
ased cause-of-death ascertainment.25-27
Our study was conducted in the early era of 
PSA testing. The current practices of performing 
repeated PSA testing, using a lower PSA thresh-
old for biopsy, obtaining more tissue-biopsy cores, 
and performing a repeat biopsy after initially nega-
tive findings increase the detection of smaller-
volume indolent cancers.15,16 Along with system-
atically higher assignment of tumor grades 
(upgrading), these factors increase the likelihood 
of overdiagnosis and overtreatment.36-38 Among 
men with a current diagnosis of prostate cancer 
who undergo radical prostatectomy, the absolute 
reductions in the risks of metastasis and death will 
probably be smaller, and the time required to 
identify a reduction will probably be longer than 
reported in our study or in the SPCG-4 trial.
Our findings support observation for men with 
localized prostate cancer, especially those who 
have a low PSA value and those who have low-risk 
disease. Up to two thirds of men who have re-
ceived a diagnosis of prostate cancer have a low 
PSA value or low-risk disease, but nearly 90% re-
ceive early intervention — typically surgery or ra-
diotherapy.1,15,16,24 In contrast to observation, ac-
tive surveillance initiates therapy with curative 
intent if disease progression is suspected on the 
Table 2. Patient-Reported Urinary, Erectile, and Bowel Dysfunction at 2 Years, 
According to Study Group.*
Dysfunction
Radical 
Prostatectomy Observation P Value
no./total no. (%)
Urinary incontinence† 49/287 (17.1) 18/284 (6.3) <0.001
Erectile dysfunction‡ 231/285 (81.1) 124/281 (44.1) <0.001
Bowel dysfunction§ 35/286 (12.2) 32/282 (11.3) 0.74
* The values reported are the number of men reporting the dysfunction and the 
total number of men who responded to the question.
† Urinary incontinence was defined by patient reports (“have a lot of problems with 
urinary dribbling,” “lose larger amounts of urine than dribbling but not all 
day,” “have no control over urine,” or “have an indwelling catheter”).
‡ Erectile dysfunction was defined as the inability to have an erection or an 
erection sufficient for vaginal penetration.
§ Bowel dysfunction was defined by patient reports that it was a “moderate” or 
“big” problem.
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basis of repeat PSA testing, digital rectal examina-
tions, and prostate biopsies.3,24 Active surveillance 
is being compared with surgery or radiotherapy 
in a randomized trial.39 Informing men of the fa-
vorable long-term effects of observation on mortal-
ity, bone metastases, urinary and erectile function, 
and quality of life40-42 and increasing the use of 
observation may avert the harms of unnecessary 
biopsies43 and interventions2,3,6 while maintain-
ing excellent long-term disease-specific survival.
In conclusion, our study showed that, as com-
pared with observation, radical prostatectomy did 
not significantly reduce all-cause or prostate-
cancer mortality through at least 12 years among 
men with clinically localized prostate cancer that 
had been diagnosed in the era of PSA testing. 
Absolute differences in mortality between the 
study groups were less than 3 percentage points. 
Subgroup analyses suggested that surgery might 
reduce mortality among men with higher PSA 
values and possibly among men with higher-risk 
tumors, but not among men with PSA levels of 
10 ng per milliliter or less or among men with 
low-risk tumors.
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